Mohs Micrographic Surgery for Primary Versus Recurrent or Incompletely Excised Facial High-risk Basal Cell Carcinomas
DOI:
https://doi.org/10.2340/00015555-3698Keywords:
basal cell carcinoma, non-melanoma skin cancer, Mohs micrographic surgery, recurrence, incomplete excisionAbstract
Facial high-risk basal cell carcinomas are preferably treated with Mohs micrographic surgery, but only 10% of patients are offered Mohs micrographic surgery in Sweden. The aim of this retrospective study was to examine the differences between primary and recurrent or incompletely excised facial high-risk basal cell carcinomas undergoing Mohs micrographic surgery, with regard to the number of stages, final defect sizes, reconstructive techniques and other consequences. The study was performed during the period 2012 to 2019 at our centre. A total of 903 basal cell carcinomas in 813 patients (70.1% primary, 10.4% incompletely excised and 19.5% recurrences) were included. The mean number of Mohs micrographic surgery stages was significantly lower for primary basal cell carcinomas compared with recurrences (p = 0.03), and the mean final defect size was significantly smaller in primary basal cell carcinomas compared with both recurrent (p < 0.0001) and incompletely excised (p = 0.003) tumours. Primary basal cell carcinomas tended to more often be reconstructed by primary closure (p = 0.08). Mohs micrographic surgery indications for facial high-risk basal cell carcinomas should be respected and used more frequently on primary basal cell carcinomas, in order to enable better utilization of resources and improved outcomes for the patient.
Downloads
References
Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069-1080.
DOI: https://doi.org/10.1111/j.1365-2133.2012.10830.x
Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 2015; 88: 167-179.
Emmett AJ. Surgical analysis and biological behaviour of 2277 basal cell carcinomas. Aust N Z J Surg 1990; 60: 855-863.
DOI: https://doi.org/10.1111/j.1445-2197.1990.tb07489.x
Rippey JJ. Why classify basal cell carcinomas? Histopathology 1998; 32: 393-398.
DOI: https://doi.org/10.1046/j.1365-2559.1998.00431.x
Kuijpers DI, Thissen MR, Neumann MH. Basal cell carcinoma: treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol 2002; 3: 247-259.
DOI: https://doi.org/10.2165/00128071-200203040-00003
Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24: 715-719.
DOI: https://doi.org/10.1016/0190-9622(91)70108-E
Swedish radiation safety authority. Eriksson T, Tinghög G. [Societal costs of skin cancer]. 2011. Available from: https://www.stralsakerhetsmyndigheten.se/publikationer/rapporter/stralskydd/2014/201449/. (in Swedish).
Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol 2002; 147: 41-47.
DOI: https://doi.org/10.1046/j.1365-2133.2002.04804.x
Jernbeck J, Glaumann B, Glas JE. [Basal cell carcinoma. Clinical evaluation of the histological grading of aggressive types of cancer]. Lakartidningen 1988; 85: 3467-3470. (in Swedish).
Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 1990; 23: 1118-1126.
DOI: https://doi.org/10.1016/0190-9622(90)70344-H
Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006; 19: S127-S147.
DOI: https://doi.org/10.1038/modpathol.3800512
Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177-1183.
DOI: https://doi.org/10.1001/archderm.135.10.1177
Swedish Society for Dermatological Surgery and Oncology (SDKO). [SDKO Guidelines for the management of squamous cell carcinoma and basal cell carcinoma]. 2016. Available from: http://ssdv.se/images/pdf/SDKOs_Riktlinjer_for_SCC__BCC_2016.pdf. (in Swedish).
Trakatelli M, Morton C, Nagore E, Ulrich C, Del Marmol V, Peris K, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol 2014; 24: 312-329.
DOI: https://doi.org/10.1684/ejd.2014.2271
Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br J Dermatol 1999; 141: 415-423.
DOI: https://doi.org/10.1046/j.1365-2133.1999.03033.x
Shriner DL, McCoy DK, Goldberg DJ, Wagner RF, Jr. Mohs micrographic surgery. J Am Acad Dermatol 1998; 39: 79-97.
DOI: https://doi.org/10.1016/S0190-9622(98)70405-0
The Swedish Cancer Registry of the National Board of Health and Welfare. [Basal cell carcinoma in Sweden 2004-2008]. 2009 Available from: www.socialstyrelsen.se. (in Swedish).
The Swedish Cancer Registry of the National Board of Health and Welfare. [Statistics on cancer incidence 2018] 2019. Available from: www.socialstyrelsen.se. (in Swedish).
Wennberg AM, Larkö O, Stenquist B. Five-year results of Mohs' micrographic surgery for aggressive facial basal cell carcinoma in Sweden. Acta Derm Venereol 1999; 79: 370-372.
DOI: https://doi.org/10.1080/000155599750010292
Paoli J, Daryoni S, Wennberg AM, Mölne L, Gillstedt M, Miocic M, et al. 5-year recurrence rates of Mohs micrographic surgery for aggressive and recurrent facial basal cell carcinoma. Acta Derm Venereol 2011; 91: 689-693.
DOI: https://doi.org/10.2340/00015555-1134
Farhi D, Dupin N, Palangié A, Carlotti A, Avril MF. Incomplete excision of basal cell carcinoma: rate and associated factors among 362 consecutive cases. Dermatol Surg 2007; 33: 1207-1214.
DOI: https://doi.org/10.1097/00042728-200710000-00008
Bassas P, Hilari H, Bodet D, Serra M, Kennedy FE, García-Patos V. Evaluation of surgical margins in basal cell carcinoma by surgical specialty. Actas Dermosifiliogr 2013; 104: 133-140.
DOI: https://doi.org/10.1016/j.ad.2012.06.001
van Loo E, Mosterd K, Krekels GA, Roozeboom MH, Ostertag JU, Dirksen CD, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. Eur J Cancer 2014; 50: 3011-3020.
DOI: https://doi.org/10.1016/j.ejca.2014.08.018
Tierney EP, Hanke CW. Cost effectiveness of Mohs micrographic surgery: review of the literature. J Drugs Dermatol 2009; 8: 914-922.
Hussain W, Affleck A, Al-Niaimi F, Cooper A, Craythorne E, Fleming C, et al. Safety, complications and patients' acceptance of Mohs micrographic surgery under local anaesthesia: results from the U.K. MAPS (Mohs Acceptance and Patient Safety) Collaboration Group. Br J Dermatol 2017; 176: 806-808.
DOI: https://doi.org/10.1111/bjd.14843
Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005; 53: 445-451.
DOI: https://doi.org/10.1016/j.jaad.2005.04.083
Santos-Arroyo A, Carrasquillo OY, Cardona R, Sánchez JL, Valentín-Nogueras S. Non-melanoma skin cancer tumor's characteristics and histologic subtype as a predictor for subclinical spread and number of Mohs stages required to achieve tumor-free margins. P R Health Sci J 2019; 38: 40-45.
Thornton JF, Carboy JA, editors. Facial reconstruction after Mohs surgery. New York (NY): Thieme; 2018.
DOI: https://doi.org/10.1055/b-0038-162368
Sclafani AP, Sclafani JA, Sclafani AM. Successes, revisions, and postoperative complications in 446 Mohs defect repairs. Facial Plast Surg 2012; 28: 358-366.
DOI: https://doi.org/10.1055/s-0032-1312691
Alam M, Ibrahim O, Nodzenski M, Strasswimmer JM, Jiang SI, Cohen JL, et al. Adverse events associated with Mohs micrographic surgery: multicenter prospective cohort study of 20,821 cases at 23 centers. JAMA Dermatol 2013; 149: 1378-1385.
DOI: https://doi.org/10.1001/jamadermatol.2013.6255
Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23: 389-402.
DOI: https://doi.org/10.1023/B:CANC.0000031775.04618.30
Miller SJ. Biology of basal cell carcinoma (Part I). J Am Acad Dermatol 1991; 24: 1-13.
DOI: https://doi.org/10.1016/0190-9622(91)70001-I
Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
DOI: https://doi.org/10.1111/j.1365-2133.2008.08666.x
Haws AL, Rojano R, Tahan SR, Phung TL. Accuracy of biopsy sampling for subtyping basal cell carcinoma. J Am Acad Dermatol 2012; 66: 106-111.
DOI: https://doi.org/10.1016/j.jaad.2011.02.042
Roozeboom MH, Kreukels H, Nelemans PJ, Mosterd K, Winnepenninckx VJ, Abdul Hamid MA, et al. Subtyping basal cell carcinoma by clinical diagnosis versus punch biopsy. Acta Derm Venereol 2015; 95: 996-998.
DOI: https://doi.org/10.2340/00015555-2113
Wolberink EA, Pasch MC, Zeiler M, van Erp PE, Gerritsen MJ. High discordance between punch biopsy and excision in establishing basal cell carcinoma subtype: analysis of 500 cases. J Eur Acad Dermatol Venereol 2013; 27: 985-989.
DOI: https://doi.org/10.1111/j.1468-3083.2012.04628.x
Sahai S, Walling HW. Factors predictive of complex Mohs surgery cases. J Dermatolog Treat 2012; 23: 421-427.
DOI: https://doi.org/10.3109/09546634.2011.579083
Smeets NW, Kuijpers DI, Nelemans P, Ostertag JU, Verhaegh ME, Krekels GA, et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face - results of a retrospective study and review of the literature. Br J Dermatol 2004; 151: 141-147.
DOI: https://doi.org/10.1111/j.1365-2133.2004.06047.x
Kuiper EM, van den Berge BA, Spoo JR, Kuiper J, Terra JB. Low recurrence rate of head and neck basal cell carcinoma treated with Mohs micrographic surgery: a retrospective study of 1021 cases. Clin Otolaryngol 2018; 43: 1321-1327.
DOI: https://doi.org/10.1111/coa.13176
Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 2005; 53: 452-457.
Published
How to Cite
License
Copyright (c) 2021 Hannah Ceder, Malin Grönberg, John Paoli
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
